Abstract:Introduction Diabetes and cancer are commonly linked together. The possible links include insulin resistance, hyperinsulinemia, hyperglycemia, oxidative stress, and chronic inflammation. These are factors that have potential promoting effects on the progression of cancer in many ways. Measurement of prostate-specific antigen (PSA) is widely applied for early detection of prostate cancer. However, several factors influence serum PSA levels in men including age, benign prostatic hyperplasia, prostatitis, and body mass index (BMI). The risk of several malignancies is increased in diabetes but the risk of prostate carcinoma in diabetic patients is reduced secondary to lowering of testosterone levels during the state of hyperinsulinemia. A negative association between serum PSA levels and metformin use is also an explanation of low cancer prostate incidence with diabetes. Objective The study aims to evaluate the PSA levels in diabetic patients with poor glycemic control i.e., glycated hemoglobin (HbA1c) ≥ 7%) vs good glycemic control (HbA1c < 7%). Materials and methods Samples of PSA in diabetic patients collected in the Department of Biochemistry at Indira Gandhi Institute of Medical Sciences (IGIMS), Patna, were included. The observational study was carried out on clinically diagnosed 318 cases of diabetes attending both the outpatient and inpatient Department, IGIMS, Patna. Six ml venous blood samples were collected from patients after obtaining informed consent and ethical clearance. Patient details regarding age, complete clinical details, and general physical examinations were recorded. Serum levels of PSA, fasting plasma glucose (FPG) and HbA1c were analyzed and values were compared. The serum level of PSA was estimated by the chemiluminescent immunoassay (CLIA) method on an automated immunoassay analyzer in the Department of Biochemistry, maintaining all the quality control precautions using a control, calibrator, and reagent kit. HbA1c estimation was by chromatography technique. Fasting plasma glucose was estimated using the hexokinase method on an automated chemistry analyzer. Statistical analyses were performed using SPSS software, version 16.0 (SPSS Inc., Chicago). The median and interquartile range were calculated for numerical variables. Covariance analysis was used in the comparisons among groups. The Mann-Whitney U test was applied to detect the comparison between the two groups. Significance was determined by the P value. P value<0.05 was considered significant. Result Serum PSA value was found to be higher in (the good glycemic control group) with a median of 0.99 with an interquartile range of 3.14, than in (the bad glycemic control group) with a median of 0.49 with an interquartile range of 3.9, and the difference is statistically significant. The difference is also statistically significant in the subgroup (i) with PSA value <4 ng/ml. In subgroups (ii) and (iii), PSA values 4 ng/ml-8 ng/ml and PSA values >8 ng/ml respectively, no significant differences were found. Conclusion It was found that serum prostate-specific antigen levels have been lower in diabetic patients with poor glycemic control than in good glycemic control. Future studies with a larger sample size and detailed information on diabetes duration and management are recommended.

The Relationship between Blood Glucose and Prostate Cancer Patients

Relationship between prostate specific antigen new parameters and Gleason score and clinical stage

Applied Research of Prostate Specific Antigen Combined with Prostate Cancer Gene 3 in Diagnosis of Prostate Disease

Relationship between diabetes mellitus and benign prostatic hyperplasia

Association of Diabetes Mellitus with Prostate Cancer Grade and Prostate-Specific Antigen in Chinese Biopsy Population

The Relationship Between Glucose Homeostasis Status and Prostate Size in Aging Chinese Males with Benign Prostatic Hyperplasia

Correlation Between Body Mass Index (BMI) and the Gleason Score of Prostate Biopsies in Chinese Population

Relationship of body mass index and blood lipid level with cancer detection on prostate biopsy

Poor Glycemic Control Affecting Screening of Prostate Carcinoma

Triglyceride-glucose index is a predictor of the risk of prostate cancer: a retrospective study based on a transprostatic aspiration biopsy population

Comparing Clinical Parameters of Abnormal and Normal Fasting Blood Glucose in Benign Prostatic Hyperplasia Patients.

Association of Type 2 Diabetes Mellitus with Pathological Grade of Prostate Cancer and Prostate-Specific Antigen

Effect of Hypertension on Bacteria Composition of Prostate Biopsy in Patients with Benign Prostatic Hyperplasia and Prostate Cancer in PSA Grey-Zone.

Serum glycosylated hemoglobin and prostate cancer risk: Results from a systematic review and dose-response meta-analysis

Significance of Indices of Blood Coagulation and Fibrinolysis Function in Patients with Prostate Cancer

The relation of prostatic volume with positive rate of prostate biopsy and the malignant grades of prostate cancer

Relationship of serum high sensitive C-reactive protein and Gleason score in patients underwent prostate biopsy

Evaluation of the accuracy of biopsy Gleason score as predictors of histological grading of prostate cancer specimens

Effect of boby mass index on positive rate of prostate cancer and Gleason score in the patients undergoing transrectal prostate biopsy

Relationship of serum PSA, f/tPSA and gleason score, clinical stage in patients with prostate cancer

Correlation of Diabetes Control with Benign Prostatic Hyperplasia in T2DM Patients